Try our Advanced Search for more refined results

Analysis

Pulled Pain Pill, Opioid Rates Show Need For Research

By Emily Field (July 10, 2017, 10:31 PM EDT) -- Endo International PLC's recent decision to yank its painkiller Opana ER from the market, following pressure from the U.S. Food and Drug Administration to stop sales of the abuse-linked drug and as prescriptions of opioids remain high in many parts of the country, points to the need for more research in treating both pain and opioid addiction....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!